Personalized Cytokine-Directed Therapy With Tocilizumab for Refractory Immune Checkpoint Inhibitor–Related Cholangiohepatitis
Open accessThe DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
INTRODUCTION For patients with corticosteroid (CS)-refractory immune checkpoint inhibitor-related cholangiohepatitis (irCH), no consensus exists regarding treatment, and outcomes remain poor. We evaluated the possibility of personalized treatment according to the patient's cytokine profile and the immunohistopathologically assessment of the predominant immune infiltrate type of liver tisssue. METHODS NSCLCs with CS-refractory irCH were analyzed by immunohistochemistry (IHC) of liver biopsy, serum cytokine panel, and CyTOF assessment of PBMC immune cell monitoring. RESULTS A total of three consecutives patients with irCH were identified. We found a predominant T-cell infiltrate and an IFN-γ/Th1 proinflammatory cytokine profile. Here, we report for the first time that a T-cell-targeted therapy with the IL-6 receptor-neutralizing antibody tocilizumab (TCZ), which inhibits signaling downstream of interferon-γ (IFN-γ) and several other JAK-dependent cytokines, is an effective single cytokine-directed therapy for CS-refractory irCH. Three patients with severe and CS-refractory irCH who were treated with TCZ showed persistent clinical and biological remission. CONCLUSION Dysregulation of the IL-6/T-cell axis may contribute to the pathogenesis of CS-refractory irCH. Our observations suggest that IL-6 blockade appears to show promise in the treatment of CS-refractory irCH. The results from our three patients need to be confirmed in a larger patient population.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Haanen, J. B. A. G., Carbonnel, F., Robert, C., Kerr, K. M., Peters, S., Larkin, J., & Jordan, K. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx225 · Cited by 2,367
Self-citationAdverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance
Martins, F., Sofiya, L., Sykiotis, G. P., Lamine, F., Maillard, M., Fraga, M., Shabafrouz, K., Ribi, C., Cairoli, A., Guex-Crosier, Y., et al. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0218-0 · Cited by 2,314
Self-citationon behalf of the Society for Immunotherapy of Cancer Toxicity Management Working Group, Puzanov, I., Diab, A., Abdallah, K., Bingham, C. O., Brogdon, C., Dadu, R., Hamad, L., Kim, S., Lacouture, M. E., et al. (2017) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-017-0300-z · Cited by 1,992
Haanen, J. B. A. G., Carbonnel, F., Robert, C., Kerr, K. M., Peters, S., Larkin, J., & Jordan, K. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy162 · Cited by 431
Self-citationBertola, A., Bonnafous, S., Anty, R., Patouraux, S., Saint-Paul, M.-C., Iannelli, A., Gugenheim, J., Barr, J., Mato, J. M., Le Marchand-Brustel, Y., et al. (2010) · PLoS ONE · doi:10.1371/journal.pone.0013577 · Cited by 240
Horisberger, A., La Rosa, S., Zurcher, J.-P., Zimmermann, S., Spertini, F., Coukos, G., & Obeid, M. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0481-0 · Cited by 81
Cited by
Brahmer, J. R., Abu-Sbeih, H., Ascierto, P. A., Brufsky, J., Cappelli, L. C., Cortazar, F. B., Gerber, D. E., Hamad, L., Hansen, E., Johnson, D. B., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-002435 · Cited by 917
Immune-related adverse events of immune checkpoint inhibitors: a review
Yin, Q., Wu, L., Han, L., Zheng, X., Tong, R., Li, L., Bai, L., & Bian, Y. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1167975 · Cited by 446
Metadata
- Authors
- Moi, L., Bouchaab, H., Mederos, N., Nguyen-Ngoc, T., Perreau, M., Fenwick, C., Vaucher, J., Sempoux, C., Peters, S., & Obeid, M.
- Venue
- Journal of Thoracic Oncology
- Publisher
- Elsevier BV
- Published
- 2021-02
- Volume
- 16
- Issue
- 2
- Pages
- 318-326
- ISSN
- 1556-0864 (ISSN-L)
- OpenAlex
- W3087739229
- Cited by
- 52
- References
- 6
- FWCI
- 1.60
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Personalized Cytokine-Directed Therapy With Tocilizumab for Refractory Immune Checkpoint Inhibitor–Related Cholangiohepatitis. https://app.cochat.ai/papers/10.1016/j.jtho.2020.09.007
- The paper
- Moi, L., Bouchaab, H., Mederos, N., Nguyen-Ngoc, T., Perreau, M., Fenwick, C., Vaucher, J., Sempoux, C., Peters, S., & Obeid, M. (2021). Personalized Cytokine-Directed Therapy With Tocilizumab for Refractory Immune Checkpoint Inhibitor–Related Cholangiohepatitis. Journal of Thoracic Oncology. https://doi.org/10.1016/j.jtho.2020.09.007
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.